183 related articles for article (PubMed ID: 28971528)
1. M2 polarization of monocytes in ankylosing spondylitis and relationship with inflammation and structural damage.
Zhao J; Yuan W; Tao C; Sun P; Yang Z; Xu W
APMIS; 2017 Dec; 125(12):1070-1075. PubMed ID: 28971528
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between sclerostin level and radiographic changes in patients with ankylosing spondylitis].
Xie J; Yu X
Zhonghua Yi Xue Za Zhi; 2015 May; 95(17):1300-4. PubMed ID: 26081658
[TBL] [Abstract][Full Text] [Related]
3. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine.
Landewé R; Dougados M; Mielants H; van der Tempel H; van der Heijde D
Ann Rheum Dis; 2009 Jun; 68(6):863-7. PubMed ID: 18628283
[TBL] [Abstract][Full Text] [Related]
4. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.
Ramiro S; van der Heijde D; van Tubergen A; Stolwijk C; Dougados M; van den Bosch F; Landewé R
Ann Rheum Dis; 2014 Aug; 73(8):1455-61. PubMed ID: 24812292
[TBL] [Abstract][Full Text] [Related]
5. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
Saad CG; Ribeiro AC; Moraes JC; Takayama L; Goncalves CR; Rodrigues MB; de Oliveira RM; Silva CA; Bonfa E; Pereira RM
Arthritis Res Ther; 2012 Oct; 14(5):R216. PubMed ID: 23062122
[TBL] [Abstract][Full Text] [Related]
6. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of serum MRP8/14 in ankylosing spondylitis: associated with peripheral arthritis and active disease.
Gupta L; Bhattacharya S; Agarwal V; Aggarwal A
Clin Rheumatol; 2016 Dec; 35(12):3075-3079. PubMed ID: 27738838
[TBL] [Abstract][Full Text] [Related]
8. The Association Between Neutrophil/Lymphocyte Ratio and Disease Activity in Rheumatoid Arthritis and Ankylosing Spondylitis.
Mercan R; Bitik B; Tufan A; Bozbulut UB; Atas N; Ozturk MA; Haznedaroglu S; Goker B
J Clin Lab Anal; 2016 Sep; 30(5):597-601. PubMed ID: 26666737
[TBL] [Abstract][Full Text] [Related]
9. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
10. Blood monocyte heterogeneity and markers of endothelial activation in ankylosing spondylitis.
Surdacki A; Sulicka J; Korkosz M; Mikolajczyk T; Telesinska-Jasiówka D; Klimek E; Kierzkowska I; Guzik T; Grodzicki TK
J Rheumatol; 2014 Mar; 41(3):481-9. PubMed ID: 24488416
[TBL] [Abstract][Full Text] [Related]
11. Suppressors of cytokine signalling in ankylosing spondylitis and their associations with disease severity, acute-phase reactants and serum cytokines.
Chen CH; Chen HA; Liao HT; Liu CH; Tsai CY; Chou CT
Clin Exp Rheumatol; 2016; 34(1):100-5. PubMed ID: 26812031
[TBL] [Abstract][Full Text] [Related]
12. Anti-agalactosyl IgG antibody in ankylosing spondylitis and psoriatic arthritis.
Chou CL; Wu MJ; Yu CL; Lu MC; Hsieh SC; Wu TH; Chou CT; Tsai CY
Clin Rheumatol; 2010 Aug; 29(8):875-81. PubMed ID: 20229261
[TBL] [Abstract][Full Text] [Related]
13. Relationship between some acute phase reactants and the Bath Ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis.
Yildirim K; Erdal A; Karatay S; Melikoğlu MA; Uğur M; Senel K
South Med J; 2004 Apr; 97(4):350-3. PubMed ID: 15108827
[TBL] [Abstract][Full Text] [Related]
14. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
[TBL] [Abstract][Full Text] [Related]
15. Serum tissue factor levels correlate with inflammation in ankylosing spondylitis.
Wendling D; Racadot E
Joint Bone Spine; 2006 Jul; 73(4):403-5. PubMed ID: 16730212
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis.
Sun W; Tian L; Jiang L; Zhang S; Zhou M; Zhu J; Xue J
Clin Rheumatol; 2019 Apr; 38(4):989-995. PubMed ID: 30443790
[TBL] [Abstract][Full Text] [Related]
17. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
Kilic E; Kilic G; Akgul O; Ozgocmen S
Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
[TBL] [Abstract][Full Text] [Related]
18. Assessment of semaphorin 3A and its role in bone remodelling in a group of ankylosing spondylitis patients.
Perrotta FM; Ceccarelli F; Barbati C; Colasanti T; Montepaone M; Alessandri C; Valesini G; Lubrano E
Clin Exp Rheumatol; 2017; 35(2):313-316. PubMed ID: 27782869
[TBL] [Abstract][Full Text] [Related]
19. TNF-α Inhibitors Decrease Classical CD14
Batko B; Schramm-Luc A; Skiba DS; Mikolajczyk TP; Siedlinski M
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30642076
[TBL] [Abstract][Full Text] [Related]
20. The VEGF and BMP-2 levels in patients with ankylosing spondylitis and the relationship to treatment with tumour necrosis factor alpha inhibitors.
Tošovský M; Bradna P; Andrýs C; Andrýsová K; Cermáková E; Soukup T
Acta Medica (Hradec Kralove); 2014; 57(2):56-61. PubMed ID: 25257151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
